109 related articles for article (PubMed ID: 30263940)
1. Novel insights into the epigenetics of diffuse glioma.
Danussi C; Huse JT
Mol Cell Oncol; 2018; 5(5):e1472055. PubMed ID: 30263940
[TBL] [Abstract][Full Text] [Related]
2. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.
Danussi C; Bose P; Parthasarathy PT; Silberman PC; Van Arnam JS; Vitucci M; Tang OY; Heguy A; Wang Y; Chan TA; Riggins GJ; Sulman EP; Lang FF; Creighton CJ; Deneen B; Miller CR; Picketts DJ; Kannan K; Huse JT
Nat Commun; 2018 Mar; 9(1):1057. PubMed ID: 29535300
[TBL] [Abstract][Full Text] [Related]
3. Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.
Malgulwar PB; Danussi C; Dharmaiah S; Johnson W; Singh A; Rai K; Rao A; Huse JT
Neuro Oncol; 2024 Jan; 26(1):55-67. PubMed ID: 37625115
[TBL] [Abstract][Full Text] [Related]
4. Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.
Malgulwar PB; Danussi C; Dharmaiah S; Johnson WE; Rao A; Huse JT
bioRxiv; 2023 Jan; ():. PubMed ID: 36711727
[TBL] [Abstract][Full Text] [Related]
5. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
[TBL] [Abstract][Full Text] [Related]
6. Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells.
Eid R; Demattei MV; Episkopou H; Augé-Gouillou C; Decottignies A; Grandin N; Charbonneau M
Mol Cell Biol; 2015 Aug; 35(16):2818-30. PubMed ID: 26055325
[TBL] [Abstract][Full Text] [Related]
7. [Application of ATRX in diagnosis and prognostic evaluation of glioma].
Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070
[No Abstract] [Full Text] [Related]
8. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma.
Wang Y; Yang J; Wild AT; Wu WH; Shah R; Danussi C; Riggins GJ; Kannan K; Sulman EP; Chan TA; Huse JT
Nat Commun; 2019 Feb; 10(1):943. PubMed ID: 30808951
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B
J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564
[TBL] [Abstract][Full Text] [Related]
10. Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6.
Kaneko MK; Yamada S; Itai S; Furusawa Y; Nakamura T; Yanaka M; Handa S; Hisamatsu K; Nakamura Y; Fukui M; Harada H; Kato Y
Biochem Biophys Rep; 2018 Sep; 15():76-80. PubMed ID: 30073207
[TBL] [Abstract][Full Text] [Related]
11. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
12. Significance of TERT and ATRX mutations in glioma.
Liu J; Zhang X; Yan X; Sun M; Fan Y; Huang Y
Oncol Lett; 2019 Jan; 17(1):95-102. PubMed ID: 30655743
[TBL] [Abstract][Full Text] [Related]
13. Alpha Thalassemia/Mental Retardation Syndrome X-Linked, the Alternative Lengthening of Telomere Phenotype, and Gliomagenesis: Current Understandings and Future Potential.
He J; Mansouri A; Das S
Front Oncol; 2017; 7():322. PubMed ID: 29359122
[TBL] [Abstract][Full Text] [Related]
14. Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.
Ogasawara S; Fujii Y; Kaneko MK; Oki H; Sabit H; Nakada M; Suzuki H; Ichimura K; Komori T; Kato Y
Monoclon Antib Immunodiagn Immunother; 2016 Oct; 35(5):254-258. PubMed ID: 27788029
[TBL] [Abstract][Full Text] [Related]
15. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
[TBL] [Abstract][Full Text] [Related]
16. [X-linked alpha-thalassemia/mental retardation syndrome].
Wada T
Rinsho Byori; 2009 Apr; 57(4):382-90. PubMed ID: 19489441
[TBL] [Abstract][Full Text] [Related]
17. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
Malzkorn B; Reifenberger G
Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013
[TBL] [Abstract][Full Text] [Related]
18. A novel missense mutation in ATRX uncovered in a Yemeni family leads to alpha-thalassemia/mental retardation syndrome without alpha-thalassemia.
Hamzeh AR; Nair P; Mohamed M; Saif F; Tawfiq N; Al-Ali MT; Bastaki F
Ir J Med Sci; 2017 May; 186(2):333-337. PubMed ID: 26860117
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape.
Panditharatna E; Yaeger K; Kilburn LB; Packer RJ; Nazarian J
Cancer Genet; 2015; 208(7-8):367-73. PubMed ID: 26206682
[TBL] [Abstract][Full Text] [Related]
20. Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome.
Schenkel LC; Kernohan KD; McBride A; Reina D; Hodge A; Ainsworth PJ; Rodenhiser DI; Pare G; Bérubé NG; Skinner C; Boycott KM; Schwartz C; Sadikovic B
Epigenetics Chromatin; 2017; 10():10. PubMed ID: 28293299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
